32
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Prolonged Disease-Free Survival after Autografting for Chemosensitive Non-Bulky Low Grade Non-Hodgkin's Lymphoma

, &
Pages 283-290 | Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Philip Campbell, Adam Friebe, Paul Foulstone, Andrew Grigg, Jennifer Hempton & Ashish Bajel. (2012) Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan–melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma. Leukemia & Lymphoma 53:7, pages 1415-1416.
Read now
Andrew P. Grigg, Janey Stone, Alvin D. Milner, Anthony P. Schwarer, Max Wolf, H. Miles Prince, John Seymour, Devinder Gill, David Ellis & John Bashford. (2010) Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leukemia & Lymphoma 51:4, pages 641-649.
Read now

Articles from other publishers (2)

J.F. Seymour, A.P. Grigg, J. Szer & R.M. Fox. (2001) Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Annals of Oncology 12:10, pages 1455-1460.
Crossref
. (2001) Current Awareness. Hematological Oncology 19:3, pages 121-128.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.